This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (previously amended): A dermal cytochrome P450 1A (CYP1A) inhibitor, wherein said dermal CYP1A inhibitor is a compound selected from the group consisting of (-)-epicatechin, (+)-epicatechin, (+)-limonene, 3-phenylpropyl acetate, α-naphthoflavone, apigenin, baicalein, baicalin, β-myrcene, catechin, β-naphthoflavone, cineole, daidzein, daidzin, diosmin, ergosterol, formononetin, gallic acid, genistein, glycyrrhizin, glycyrrhizic acid, hesperetin, hesperidin, isoquercitrin, kaempferol, lauryl alcohol, luteolin, luteolin-7-glycoside, narigin, nordihydroguaiaretic acid, oleanolic acid, paeoniflorin, quercitrin, rutin, swertiamarin, terpineol, trans-cinnamaldehyde, trans-cinnamic acid, umbelliferone, genkwanin, homoorientin, isovitexin, neohesperidin, wongonin, capillarisin, liquiritin, ethyl myristate, poncirin, and ursolic acid.

Claim 2. (previously amended): The dermal cytochrome P450 1A (CYP1A) inhibitor according to claim 1, wherein said dermal CYP1A inhibitor is a compound selected from the group consisting of kaempferol, luteolin-7-glycoside, terpineol, ~~α-naphthoflavone~~, β-naphthoflavone, and hesperetin.

Claims 3-9 (cancelled)

Claims 10-16 (withdrawn)

Claim 17 (previously added): A pharmaceutical composition comprising a free base or pharmaceutically acceptable salt of at least one of the dermal CYP1A inhibitor according to claim 1.

Claim 18 (currently amended): The pharmaceutical composition according to claim 17, wherein said pharmaceutical composition inhibits <u>a dermal</u> cytochrome P450 1A enzymatic activity.

Claim 19 (previously added): The pharmaceutical composition according to claim 17, wherein said pharmaceutical composition is topically administered to a mammal.

Claim 20 (currently amended): The pharmaceutical composition according to claim 18, wherein said pharmaceutical composition inhibits said dermal cytochrome P450 1A enzymatic activity of performing ~~is~~ a first-pass metabolism of a drug when said drug is applied to a skin of a mammal.

Claim 21 (previously added): The pharmaceutical composition according to claim 20, wherein said drug is a dermatological drug.

Claim 22 (previously added): The pharmaceutical composition according to claim 21, wherein said dermatological drug is retinoid.

Claim 23 (previously added): The pharmaceutical composition according to claim 21, wherein said dermatological drug is retinoic acid.

Claim 24 (currently amended): The pharmaceutical composition according to claim 21, wherein said dermatological drug is topically co-administered with a therapeutic effective amount of said pharmaceutical composition to a mammal.

Claim 25 (previously added): The pharmaceutical composition according to claim 18, wherein said pharmaceutical composition inhibits said dermal cytochrome 450 1A enzymatic activity of converting ~~converts~~ a chemical into a carcinogen when said chemical is in contact with skin of a mammal.

Claim 26 (previously added): The pharmaceutical composition according to claim 25, wherein said carcinogen causes skin cancer in a mammal.

Claim 27 (currently amended): The dermal cytochrome P450 1A (CYP1A) inhibitor according to claim 1, wherein said dermal CYP1A inhibitor is a compound selected from the

group consisting of ~~α-naphthoflavone~~, β-naphthoflavone, kaempferol, trans-cinnamaldehyde, and luteolin.

Claim 28 (currently amended): A liver cytochrome P450 1A (CYP1A) inhibitor, wherein said ~~dermal~~ liver CYP1A inhibitor is the compound according to claim 27.

Claim 29 (currently amended): The liver CYP1A inhibitor according to claim 28, wherein said ~~hepatic~~ liver CYP1A inhibitor is ~~α-naphthoflavone,~~ β-naphthoflavone, or trans-cinnamaldehyde.

Claim 30 (currently amended): A pharmaceutical composition comprising a free base or a pharmaceutically acceptable salt of said liver CYP1A inhibitor according to claim 28.

Claim 31 (previously added): The pharmaceutical composition according to claim 30, wherein said pharmaceutical composition inhibits liver cytochrome P450 1A enzymatic activity.

Claim 32 (currently amended): The pharmaceutical composition according to claim 31, wherein said pharmaceutical composition inhibits said liver cytochrome P450 1A enzymatic activity of performing ~~is~~ a first-pass metabolism of a drug when said drug is orally administered to a mammal.